NCT07066072View on ClinicalTrials.gov

The Radiofrequency Therapy in Management of Sickle Cell Disease Chronic Pain RCT Tested the Effect of TECAR Therapy on Sickle Cell Disease Chronic Pain.

NACompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

January 1, 2025

Study Completion Date

March 30, 2025

Conditions
the Use of Radiofrequency Ablation in Form of TECAR(Capacitive and Resistive Transfer Energy) in Chronic Pain of Sickle Cell Disease Patients
Interventions
DEVICE

Tecar therapy (TECAR: Capacitive and Resistive Energy Transfer).

the Tecar therapy (TECAR: Capacitive and Resistive Energy Transfer) will be assigned to TECAR group

OTHER

standard pharmacological therapy in sickle cell disease like hydroxyurea,paracetamol,ibubrofen and blood transfusion if needed

this is the standard medical care assigned to control group

Trial Locations (1)

12613

Cairo University, Cairo

All Listed Sponsors
lead

Cairo University

OTHER